This company has been marked as potentially delisted and may not be actively trading. Bioanalytical Systems (BASI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock BASI vs. AIKI, LUNA, DKDCA, QNTM, ACRV, TELA, NEUE, ALGS, CUE, and ICCCShould you be buying Bioanalytical Systems stock or one of its competitors? The main competitors of Bioanalytical Systems include AIkido Pharma (AIKI), Luna Innovations (LUNA), Data Knights Acquisition (DKDCA), Quantum Biopharma (QNTM), Acrivon Therapeutics (ACRV), TELA Bio (TELA), NeueHealth (NEUE), Aligos Therapeutics (ALGS), Cue Biopharma (CUE), and ImmuCell (ICCC). Bioanalytical Systems vs. Its Competitors AIkido Pharma Luna Innovations Data Knights Acquisition Quantum Biopharma Acrivon Therapeutics TELA Bio NeueHealth Aligos Therapeutics Cue Biopharma ImmuCell AIkido Pharma (NASDAQ:AIKI) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Which has preferable earnings and valuation, AIKI or BASI? Bioanalytical Systems has higher revenue and earnings than AIkido Pharma. Bioanalytical Systems is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIkido PharmaN/AN/A-$7.17M-$3.88-1.56Bioanalytical Systems$60.47M0.26-$4.68M-$0.35-4.03 Is AIKI or BASI more profitable? AIkido Pharma has a net margin of 0.00% compared to Bioanalytical Systems' net margin of -7.75%. AIkido Pharma's return on equity of -18.21% beat Bioanalytical Systems' return on equity.Company Net Margins Return on Equity Return on Assets AIkido PharmaN/A -18.21% -16.94% Bioanalytical Systems -7.75%-42.74%-6.38% Do institutionals & insiders have more ownership in AIKI or BASI? 10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 11.5% of Bioanalytical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, AIKI or BASI? AIkido Pharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Does the media refer more to AIKI or BASI? In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Bioanalytical Systems'average media sentiment score. Company Overall Sentiment AIkido Pharma Neutral Bioanalytical Systems Neutral SummaryBioanalytical Systems beats AIkido Pharma on 6 of the 10 factors compared between the two stocks. Get Bioanalytical Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BASI vs. The Competition Export to ExcelMetricBioanalytical SystemsCommercial Physical Research IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.70M$26.99M$6.05B$10.51BDividend YieldN/AN/A5.73%4.80%P/E Ratio-3.36N/A85.3627.35Price / Sales0.260.36516.10196.40Price / Cash558.4057.2337.5761.53Price / Book2.040.3112.426.82Net Income-$4.68M-$525K$3.32B$276.80M Bioanalytical Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BASIBioanalytical SystemsN/A$1.41+2.9%N/A-25.5%$15.70M$60.47M-3.36397AIKIAIkido PharmaN/A$7.42+1.8%N/A+244.8%$40.70MN/A-1.914Gap UpHigh Trading VolumeLUNALuna InnovationsN/A$1.14+0.9%N/A-28.1%$38.71M$116.61M0.00390DKDCAData Knights AcquisitionN/A$1.03-1.0%N/A-61.9%$5.33MN/A-5.422Gap DownHigh Trading VolumeQNTMQuantum Biopharma0.4253 of 5 stars$16.12-6.2%N/A+231.7%$61.55MN/A-1.15N/AACRVAcrivon Therapeutics2.3153 of 5 stars$1.96+2.4%$15.00+667.3%-76.0%$61.35MN/A-0.8758TELATELA Bio2.3328 of 5 stars$1.56-1.0%$4.50+189.4%-40.2%$61.02M$69.30M-1.37120News CoverageGap UpNEUENeueHealth1.4314 of 5 stars$6.75flat$7.00+3.7%N/A$60.94M$890.44M-0.421,252ALGSAligos Therapeutics3.8917 of 5 stars$9.83-0.1%$50.00+408.6%+33.6%$60.45M$3.94M-0.5090News CoverageGap DownCUECue Biopharma2.7093 of 5 stars$0.78+3.4%N/A-34.1%$59.79M$9.29M-1.3960News CoveragePositive NewsAnalyst ForecastICCCImmuCell1.1287 of 5 stars$6.60+2.2%N/A+82.6%$59.69M$26.49M34.7170 Related Companies and Tools Related Companies AIkido Pharma Competitors Luna Innovations Competitors Data Knights Acquisition Competitors Quantum Biopharma Competitors Acrivon Therapeutics Competitors TELA Bio Competitors NeueHealth Competitors Aligos Therapeutics Competitors Cue Biopharma Competitors ImmuCell Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BASI) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioanalytical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioanalytical Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
